drugset / Trial / NCT00019214
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
Treatment
Summary
RATIONALE: Vaccines made from white blood cells treated with antigens may make the body build an immune response to kill melanoma cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may kill more melanoma cells. PURPOSE: This phase I/II trial is studying the side effects and how well giving vaccine therapy and interleukin-2 works compared to vaccine therapy alone in treating patients with metastatic melanoma that has not responded to previous therapy.
Timeline
- Start
- 1997-04
- Primary completion
- —
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MART-1 antigen | Vaccine | — | Other |
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |
| Subject | gp100 antigen | Peptide | — | Other |